An Electrically Tight In Vitro Blood–Brain Barrier Model Displays Net Brain-to-Blood Efflux of Substrates for the ABC Transporters, P-gp, Bcrp and Mrp-1

Abstract

Efflux transporters of the ATP-binding cassette superfamily including breast cancer resistance protein (Bcrp/Abcg2), P-glycoprotein (P-gp/Abcb1) and multidrug resistance-associated proteins (Mrp’s/Abcc’s) are expressed in the blood–brain barrier (BBB). The aim of this study was to investigate if a bovine endothelial/rat astrocyte in vitro BBB co-culture model displayed polarized transport of known efflux transporter substrates. The co-culture model displayed low mannitol permeabilities of 0.95 ± 0.1 · 10−6 cm·s−1 and high transendothelial electrical resistances of 1,177 ± 101 Ω·cm2. Bidirectional transport studies with 3H-digoxin, 3H-estrone-3-sulphate and 3H-etoposide revealed polarized transport favouring the brain-to-blood direction for all substrates. Steady state efflux ratios of 2.5 ± 0.2 for digoxin, 4.4 ± 0.5 for estrone-3-sulphate and 2.4 ± 0.1 for etoposide were observed. These were reduced to 1.1 ± 0.08, 1.4 ± 0.2 and 1.5 ± 0.1, by addition of verapamil (digoxin), Ko143 (estrone-3-sulphate) or zosuquidar + reversan (etoposide), respectively. Brain-to-blood permeability of all substrates was investigated in the presence of the efflux transporter inhibitors verapamil, Ko143, zosuquidar, reversan and MK 571 alone or in combinations. Digoxin was mainly transported via P-gp, estrone-3-sulphate via Bcrp and Mrp’s and etoposide via P-gp and Mrp’s. The expression of P-gp, Bcrp and Mrp-1 was confirmed using immunocytochemistry. The findings indicate that P-gp, Bcrp and at least one isoform of Mrp are functionally expressed in our bovine/rat co-culture model and that the model is suitable for investigations of small molecule transport.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    Di L, Rong H, Feng B. Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J Med Chem. 2013;56(1):2–12.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37(1):13–25.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105–27.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Schinkel AH. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev. 1999;36(2–3):179–94.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695–8.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  6. 6.

    Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier. Brain Res. 2003;971(2):221–31.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, et al. Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–45.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Geier EG, Chen EC, Webb A, Papp AC, Yee SW, Sadee W, et al. Profiling solute carrier transporters in the human blood–brain barrier. Clin Pharmacol Ther. 2013;94(6):636–9.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  9. 9.

    Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 2000;876(1–2):148–53.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol. 2004;24(17):7612–21.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  11. 11.

    Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos. 2007;35(4):660–6.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Nicolazzo JA, Katneni K. Drug transport across the blood–brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem. 2009;9(2):130–47.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58(2):140–61.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Abbott NJ, Dolman DM, Yusof S, Reichel A, et al. In Vitro Models of CNS Barriers. In: Hammarlund-Udenaes M, de Lange ECM, editors. Drug delivery to the brain. New York: Springer; 2014. p. 163–97.

    Google Scholar 

  16. 16.

    Fontaine M, Elmquist WF, Miller DW. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci. 1996;59(18):1521–31.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Lechardeur D, Scherman D. Functional expression of the P-glycoprotein mdr in primary cultures of bovine cerebral capillary endothelial cells. Cell Biol Toxicol. 1995;11(5):283–93.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 1992;51(18):1427–37.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood–brain barrier. Pharm Res. 2000;17(10):1198–205.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Hakkarainen JJ, Rilla K, Suhonen M, Ruponen M, Forsberg MM. Re-evaluation of the role of P-glycoprotein in in vitro drug permeability studies with the bovine brain microvessel endothelial cells. Xenobiotica; Fate Foreign Compd Biol Syst. 2014;44(3):283–94.

    CAS  Article  Google Scholar 

  21. 21.

    Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer VV, Duhem C, et al. In vitro model for evaluating drug transport across the blood–brain barrier. Adv Drug Deliv Rev. 1999;36(2–3):165–78.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    van der Sandt IC, Smolders R, Nabulsi L, Zuideveld KP, de Boer AG, Breimer DD. Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood–brain barrier. Eur J Pharm Sci. 2001;14(1):81–6.

    PubMed  Article  Google Scholar 

  23. 23.

    van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier. AIDS. 2001;15(4):483–91.

    PubMed  Article  Google Scholar 

  24. 24.

    Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, et al. In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther. 2013;94(1):95–112.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Crone C, Olesen SP. Electrical resistance of brain microvascular endothelium. Brain Res. 1982;241(1):49–55.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood–brain barrier in anaesthetized rats: a developmental study. J Physiol. 1990;429:47–62.

    CAS  PubMed Central  PubMed  Google Scholar 

  27. 27.

    Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, et al. In vitro models for the blood–brain barrier. Toxicol In Vitro. 2005;19(3):299–334.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Avdeef A. How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood–brain barrier permeability? Eur J Pharm Sci. 2011;43(3):109–24.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Sjostedt N, Kortejarvi H, Kidron H, Vellonen KS, Urtti A, Yliperttula M. Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood–brain barrier. Pharm Res. 2014;31(1):1–19.

    PubMed  Article  Google Scholar 

  30. 30.

    Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, et al. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54(3–4):253–63.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, et al. Establishment and functional characterization of an in vitro model of the blood–brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci. 2001;12(3):215–22.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Helms HC, Waagepetersen HS, Nielsen CU, Brodin B. Paracellular tightness and claudin-5 expression is increased in the BCEC/astrocyte blood–brain barrier model by increasing media buffer capacity during growth. AAPS J. 2010;12(4):759–70.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  33. 33.

    Helms HC, Brodin B. Generation of primary cultures of bovine brain endothelial cells and setup of cocultures with rat astrocytes. Methods Mol Biol. 2014;1135:365–82.

    PubMed  Article  Google Scholar 

  34. 34.

    Helms HC, Madelung R, Waagepetersen HS, Nielsen CU, Brodin B. In vitro evidence for the brain glutamate efflux hypothesis: brain endothelial cells cocultured with astrocytes display a polarized brain-to-blood transport of glutamate. Glia. 2012;60(6):882–93.

    PubMed  Article  Google Scholar 

  35. 35.

    Hertz L, Juurlink BHJ, Hertz E, Fosmark H. Preparation of primary cultures of mouse (rat) astrocytes. In: Shahar A, Vellis JVAD, Haber B, editors. A dissection and tissue culture manual of the nervous system. New York: Alan R. Liss, Inc; 1989. p. 105-8.

  36. 36.

    Hosoya K, Asaba H, Terasaki T. Brain-to-blood efflux transport of estrone-3-sulfate at the blood–brain barrier in rats. Life Sci. 2000;67(22):2699–711.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Xia CQ, Liu N, Yang D, Miwa G, Gan LS. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos. 2005;33(5):637–43.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Ma JD, Tsunoda SM, Bertino Jr JS, Trivedi M, Beale KK, Nafziger AN. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010;49(4):223–37.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95–117.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Matsson P, Englund G, Ahlin G, Bergstrom CA, Norinder U, Artursson P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther. 2007;323(1):19–30.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009;26(8):1816–31.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003;20(8):1200–9.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003;278(25):22644–9.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Guo A, Marinaro W, Hu P, Sinko PJ. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002;30(4):457–63.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995;55(22):5342–7.

    CAS  PubMed  Google Scholar 

  46. 46.

    Liu WH, Liu HB, Gao DK, Ge GQ, Zhang P, Sun SR, et al. ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway. Cell Transplant. 2013;22(10):1859–68.

    PubMed  Article  Google Scholar 

  47. 47.

    Perrotton T, Trompier D, Chang XB, Di Pietro A, Baubichon-Cortay H. (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem. 2007;282(43):31542–8.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006;34(5):786–92.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Takara K, Matsubara M, Yamamoto K, Minegaki T, Takegami S, Takahashi M, et al. Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells. Mol Med Reports. 2012;5(3):603–9.

    CAS  Google Scholar 

  50. 50.

    Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28(6):655–60.

    CAS  PubMed  Google Scholar 

  51. 51.

    Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999;290(2):854–62.

    CAS  PubMed  Google Scholar 

  52. 52.

    Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007;59(2):238–45.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun. 1995;208(1):345–52.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003;63(5):1094–103.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, et al. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol. 2003;16(12):1642–51.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 2009;69(16):6573–80.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  57. 57.

    Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96(4):1698–705.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  58. 58.

    Yue W, Abe K, Brouwer KL. Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol Pharm. 2009;6(1):134–43.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  59. 59.

    Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009;297(2):G371–7.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Fenart L, Buee-Scherrer V, Descamps L, Duhem C, Poullain MG, Cecchelli R, et al. Inhibition of P-glycoprotein: rapid assessment of its implication in blood–brain barrier integrity and drug transport to the brain by an in vitro model of the blood–brain barrier. Pharm Res. 1998;15(7):993–1000.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Luo S, Pal D, Shah SJ, Kwatra D, Paturi KD, Mitra AK. Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids. Mol Pharm. 2010;7(2):412–20.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  62. 62.

    Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, et al. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer. 1995;72(2):418–23.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  63. 63.

    Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, et al. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res. 2005;22(12):2023–34.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001;7(4):935–41.

    CAS  PubMed  Google Scholar 

  65. 65.

    Mease K, Sane R, Podila L, Taub ME. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012;101(5):1888–97.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Qian YM, Song WC, Cui H, Cole SP, Deeley RG. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem. 2001;276(9):6404–11.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997;94(20):10594–9.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  68. 68.

    Zhang Y, Li CS, Ye Y, Johnson K, Poe J, Johnson S, et al. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood–brain barrier permeability. Drug Metab Dispos. 2006;34(11):1935–43.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Gaillard PJ, de Boer AG. Relationship between permeability status of the blood–brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci. 2000;12(2):95–102.

    CAS  PubMed  Article  Google Scholar 

  70. 70.

    Lemmen J, Tozakidis IE, Bele P, Galla HJ. Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood–brain barrier after CITCO activation. Brain Res. 2013;1501:68–80.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Lemmen J, Tozakidis IE, Galla HJ. Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood–brain barrier. Brain Res. 2013;1491:1–13.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Birger Brodin.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Helms, H.C., Hersom, M., Kuhlmann, L.B. et al. An Electrically Tight In Vitro Blood–Brain Barrier Model Displays Net Brain-to-Blood Efflux of Substrates for the ABC Transporters, P-gp, Bcrp and Mrp-1. AAPS J 16, 1046–1055 (2014). https://doi.org/10.1208/s12248-014-9628-1

Download citation

KEY WORDS

  • blood–brain barrier
  • breast cancer resistance protein
  • multidrug resistance-associated protein
  • p-glycoprotein
  • polarized small molecule transport